The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Open accessAbstract
Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein degradation tool developed in recent years that can ubiquitinate the target proteins through the ubiquitin-proteasome system (UPS) to achieve an effect on tumor growth. A number of literature studies on PROTAC technology have proved an insight into the feasibility of PROTAC technology to degrade target proteins. Additionally, the first oral PROTACs (ARV-110 and ARV-471) have shown encouraging results in clinical trials for prostate and breast cancer treatment, which inspires a greater enthusiasm for PROTAC research. Here we focus on the structures and mechanisms of PROTACs and describe several classes of effective PROTAC degraders based on E3 ligases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
The ubiquitin-proteasome system
Nandi, D., Tahiliani, P., Kumar, A., & Chandu, D. (2006) · Journal of Biosciences · doi:10.1007/bf02705243 · Cited by 758
BRD4 and Cancer: going beyond transcriptional regulation
Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0915-9 · Cited by 708
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Self-citationSmall‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Targeted protein degradation by PROTACs
Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
IAP-targeted therapies for cancer
LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., & Korneluk, R. G. (2008) · Oncogene · doi:10.1038/onc.2008.302 · Cited by 524
Polycomb-Dependent H3K27me1 and H3K27me2 Regulate Active Transcription and Enhancer Fidelity
Ferrari, K. J., Scelfo, A., Jammula, S., Cuomo, A., Barozzi, I., Stützer, A., Fischle, W., Bonaldi, T., & Pasini, D. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.10.030 · Cited by 512
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
Buckley, D. L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J. L., Smith, I. E., Miah, A. H., Harling, J. D., & Crews, C. M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00442 · Cited by 488
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Myeku, N., Clelland, C. L., Emrani, S., Kukushkin, N. V., Yu, W. H., Goldberg, A. L., & Duff, K. E. (2016) · Nature Medicine · doi:10.1038/nm.4011 · Cited by 446
Gan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., & Guo, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0122-2 · Cited by 426
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., & Deshaies, R. J. (2003) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t300009-mcp200 · Cited by 425
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
Itoh, Y., Ishikawa, M., Naito, M., & Hashimoto, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100691p · Cited by 404
Protein–protein interactions in human disease
RYAN, D., & MATTHEWS, J. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.06.001 · Cited by 375
Hines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2918 · Cited by 348
Strategies and Approaches of Targeting STAT3 for Cancer Treatment
Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00945 · Cited by 347
Yuan, L., Xu, Z.-Y., Ruan, S.-M., Mo, S., Qin, J.-J., & Cheng, X.-D. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01219-0 · Cited by 329
Self-citationRole of HIF-1 in Cancer Progression: Novel Insights. A Review
Pezzuto, A., & Carico, E. (2019) · Current Molecular Medicine · doi:10.2174/1566524018666181109121849 · Cited by 305
Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302
Sun, Y., Zhao, X., Ding, N., Gao, H., Wu, Y., Yang, Y., Zhao, M., Hwang, J., Song, Y., Liu, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0055-1 · Cited by 295
The PROTAC technology in drug development
Zou, Y., Ma, D., & Wang, Y. (2019) · Cell Biochemistry and Function · doi:10.1002/cbf.3369 · Cited by 295
Coats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 289
Mangal, S., Gao, W., Li, T., & Zhou, Q. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.34 · Cited by 288
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100681 · Cited by 255
Self-citationTargeting Cdc20 as a novel cancer therapeutic strategy
Wang, L., Zhang, J., Wan, L., Zhou, X., Wang, Z., & Wei, W. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.002 · Cited by 251
Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01530 · Cited by 233
Impact of linker length on the activity of PROTACs
Cyrus, K., Wehenkel, M., Choi, E.-Y., Han, H.-J., Lee, H., Swanson, H., & Kim, K.-B. (2010) · Molecular BioSystems · doi:10.1039/c0mb00074d · Cited by 232
The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
Hou, H., Sun, D., & Zhang, X. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0937-4 · Cited by 231
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
Burslem, G. M., Schultz, A. R., Bondeson, D. P., Eide, C. A., Savage Stevens, S. L., Druker, B. J., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1236 · Cited by 212
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
Neklesa, T., Snyder, L. B., Willard, R. R., Vitale, N., Pizzano, J., Gordon, D. A., Bookbinder, M., Macaluso, J., Dong, H., Ferraro, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.259 · Cited by 208
Han, X., Zhao, L., Xiang, W., Qin, C., Miao, B., Xu, T., Wang, M., Yang, C.-Y., Chinnaswamy, K., Stuckey, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01393 · Cited by 208
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
Zhang, J., Wu, T., Simon, J., Takada, M., Saito, R., Fan, C., Liu, X.-D., Jonasch, E., Xie, L., Chen, X., et al. (2018) · Science · doi:10.1126/science.aap8411 · Cited by 203
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
Su, S., Yang, Z., Gao, H., Yang, H., Zhu, S., An, Z., Wang, J., Li, Q., Chandarlapaty, S., Deng, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00871 · Cited by 199
PROTACs: A novel strategy for cancer therapy
Liu, J., Ma, J., Liu, Y., Xia, J., Li, Y., Wang, Z. P., & Wei, W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.006 · Cited by 186 · cited 1×
“All of these factors limit the development of SMIs in cancer treatment (Liu et al., 2020).”
BackgroundDegradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Potjewyd, F., Turner, A.-M. W., Beri, J., Rectenwald, J. M., Norris-Drouin, J. L., Cholensky, S. H., Margolis, D. M., Pearce, K. H., Herring, L. E., & James, L. I. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.006 · Cited by 175
Petrylak, D. P., Gao, X., Vogelzang, N. J., Garfield, M. H., Taylor, I., Dougan Moore, M., Peck, R. A., & Burris, H. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3500 · Cited by 169 · cited 1×
“The early reported data (by January 2020) from the first-in-human, phase I study of ARV-110 demonstrated its safety and tolerability in patients with metastatic castrateresistant prostate cancer (mCRPC) (Petrylak et al., 2020).”
BackgroundCereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
Girardini, M., Maniaci, C., Hughes, S. J., Testa, A., & Ciulli, A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.048 · Cited by 169
New Promise and Opportunities for Allosteric Kinase Inhibitors
Lu, X., Smaill, J. B., & Ding, K. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201914525 · Cited by 164
Recent Advances in the Development of Indazole‐based Anticancer Agents
Dong, J., Zhang, Q., Wang, Z., Huang, G., & Li, S. (2018) · ChemMedChem · doi:10.1002/cmdc.201800253 · Cited by 161
Self-citationQi, S.-M., Cheng, G., Cheng, X.-D., Xu, Z., Xu, B., Zhang, W.-D., & Qin, J.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00233 · Cited by 159
Self-citationKregel, S., Wang, C., Han, X., Xiao, L., Fernández‐Salas, E., Bawa, P., McCollum, B. L., Wilder-Romans, K., Apel, I. J., Cao, X., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2019.12.003 · Cited by 144
VHL and Hypoxia Signaling: Beyond HIF in Cancer
Zhang, J., & Zhang, Q. H. (2018) · Biomedicines · doi:10.3390/biomedicines6010035 · Cited by 140
Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer
Flanagan, J., Qian, Y., Gough, S. M., Andreoli, M., Bookbinder, M., Cadelina, G. W., Bradley, J., Rousseau, E., Willard, R. R., Pizzano, J., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p5-04-18 · Cited by 139
Zhao, Q., Ren, C., Liu, L., Chen, J., Shao, Y., Sun, N., Sun, R., Kong, Y., Ding, X., Zhang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01264 · Cited by 134
Zhang, H., Zhao, H., Xi, X.-X., Liu, Y., Xin, M., Mao, S., Zhang, J., Lu, A., & Zhang, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112061 · Cited by 133
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Emerging Paradigm of Crosstalk between Autophagy and the Ubiquitin-Proteasome System.
Nam, T., Han, J. H., Devkota, S., & Lee, H. (2017) · PubMed Central · doi:10.14348/molcells.2017.0226 · Cited by 126
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Wolska, A., & Robak, T. (2019) · Drug Safety · doi:10.1007/s40264-018-0775-7 · Cited by 124
Qin, J., Li, X., Hunt, C., Wang, W., Wang, H., & Zhang, R. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.07.002 · Cited by 123
Self-citationDevelopment of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
Ohoka, N., Tsuji, G., Shoda, T., Fujisato, T., Kurihara, M., Demizu, Y., & Naito, M. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00704 · Cited by 123
Development of selective mono or dual PROTAC degrader probe of CDK isoforms
Zhou, F., Chen, L., Cao, C.-G., Yu, J., Luo, X., Zhou, P., Zhao, L., Du, W., Cheng, J., Xie, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111952 · Cited by 121
Development and Characterization of a Wee1 Kinase Degrader
Li, Z., Pinch, B. J., Olson, C. M., Donovan, K. A., Nowak, R. P., Mills, C. E., Scott, D. A., Doctor, Z. M., Eleuteri, N. A., Chung, M., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.10.013 · Cited by 111
Protein degradation through covalent inhibitor-based PROTACs
Xue, G., Chen, J., Liu, L., Zhou, D., Zuo, Y., Fu, T., & Pan, Z. (2020) · Chemical Communications · doi:10.1039/c9cc08238g · Cited by 111
Plasticity in designing PROTACs for selective and potent degradation of HDAC6
Yang, H., Lv, W., He, M., Deng, H., Li, H., Wu, W., & Rao, Y. (2019) · Chemical Communications · doi:10.1039/c9cc08509b · Cited by 108
Mendoza, M. J., Mandani, G., & Momand, J. A. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0027 · Cited by 96
Targeting MDM2 for novel molecular therapy: Beyond oncology
Wang, W., Qin, J., Rajaei, M., Li, X., Yu, X., Hunt, C., & Zhang, R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21637 · Cited by 94
Self-citationPROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
Sun, X., & Rao, Y. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00848 · Cited by 93
Sun, D.-Y., Wu, J., He, Z., He, M., & Sun, H. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116791 · Cited by 89
Jaime-Figueroa, S., Buhimschi, A. D., Toure, M., Hines, J., & Crews, C. M. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126877 · Cited by 88
Zhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications · doi:10.1039/c9cc07217a · Cited by 86
Smac Mimetics to Therapeutically Target IAP Proteins in Cancer
Fulda, S. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.004 · Cited by 78
Dai, G., Sun, B., Gong, T., Pan, Z., Meng, Q., & Ju, W. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.10.025 · Cited by 78
Calzada, M. J., Esteban, M. A., Feijoo‐Cuaresma, M., Castellanos, M. C., Naranjo‐Suarez, S., Temes, E., Méndez, F., Yáñez‐Mó, M., Ohh, M., & Landázuri, M. O. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3236 · Cited by 77
The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?
Xu, J., Li, Y., Tang, Y., Xu, Z., Xu, H.-D., Cheng, X., & Qin, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621428 · Cited by 71
Self-citationA novel strategy to block mitotic progression for targeted therapy
Chi, J. J., Li, H., Zhou, Z., Izquierdo-Ferrer, J., Xue, Y., Wavelet, C. M., Schiltz, G. E., Zhang, B., Cristofanilli, M., Lu, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.013 · Cited by 70
Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer
Neklesa, T. K., Snyder, L. B., Willard, R. R., Vitale, N., Raina, K., Pizzano, J., Gordon, D., Bookbinder, M., Macaluso, J., Dong, H., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5236 · Cited by 65
Shi, C., Zhang, H., Wang, P., Wang, K., Xu, D., Wang, H., Yin, L., Zhang, S., & Zhang, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2022-2 · Cited by 61
Zhou, L., Chen, W.-M., Cao, C., Shi, Y., Ye, W., Hu, J., Wang, L., & Zhou, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112028 · Cited by 59
Ohoka, N., Ujikawa, O., Shimokawa, K., Sameshima, T., Shibata, N., Hattori, T., Nara, H., Cho, N., & Naito, M. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00567 · Cited by 57
Design, Synthesis, and Biological Evaluation of MEK PROTACs
Vollmer, S., Cunoosamy, D. M., Lv, H., Feng, H., Li, X., Nan, Z., Yang, W., & Perry, M. W. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00810 · Cited by 57
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
Yu, D.-H., Xu, Z., Mo, S., Li, Y., Cheng, X., & Qin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01389 · Cited by 54
Self-citationMDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53
Wang, W., Cheng, J., Qin, J., Hu, B., Li, X., Nijampatnam, B., Velu, S. E., Fan, J., Yang, X., & Zhang, R. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.114429 · Cited by 53
Self-citationMu, X., Bai, L., Xu, Y., Wang, J., & Lu, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.007 · Cited by 52
Zhang, F., Wu, Z., Chen, P., Zhang, J., Wang, T., Zhou, J., & Zhang, H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115228 · Cited by 51
Development of a PDEδ‐Targeting PROTACs that Impair Lipid Metabolism
Winzker, M., Friese, A., Koch, U., Janning, P., Ziegler, S., & Waldmann, H. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201913904 · Cited by 48
Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α
Dai, Y., Na, Y., Gong, J., Liu, C., Li, Q., Zhou, J., Huang, W., & Qian, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111967 · Cited by 44
Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
Kim, K., Lee, D.-H., Park, S., Jo, S.-H., Ku, B., Park, S. G., Park, B. C., Jeon, Y. U., Ahn, S., Kang, C. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56177-5 · Cited by 39
Degrading proteins in animals: “PROTAC”tion goes in vivo
Guo, J., Liu, J., & Wei, W. (2019) · Cell Research · doi:10.1038/s41422-019-0144-9 · Cited by 38
Wang, W., Yang, J., Liao, Y., Cheng, G., Chen, J., Mo, S., Li, Y., Cheng, X., Qin, J., & Shao, Z. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00189 · Cited by 37
Self-citationWang, X., He, Q., Wu, K., Guo, T., Du, X., Zhang, H., Fang, L., Zheng, N., Zhang, Q., & Ye, F. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.017 · Cited by 24
The E2 ubiquitin-conjugating enzyme UbcH5c: an emerging target in cancer and immune disorders
Zhou, Y., Chen, R., Luo, X., Zhang, W., & Qin, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.015 · Cited by 24
Self-citationExperimental Therapy of Advanced Breast Cancer: Targeting NFAT1–MDM2–p53 Pathway
Qin, J., Wang, W., & Zhang, R. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.07.005 · Cited by 23
Self-citationInduced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
Groppe, J. C. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660641 · Cited by 23
Feng, Y., Su, H., Li, Y., Luo, C., Xu, H., Wang, Y., Sun, H., Wan, G., Zhou, B., & Bu, X. (2020) · Chemical Communications · doi:10.1039/c9cc08391j · Cited by 22
Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199
Naqvi, K., Konopleva, M. Y., & Ravandi, F. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1366852 · Cited by 19
Expanding the Degradable Proteome: Designing PROTACs by the Book
Jaeger, M. G., & Winter, G. E. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2019.12.009 · Cited by 14
Cited by
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Self-citationTargeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
An overview of PROTACs: a promising drug discovery paradigm
Liu, Z., Hu, M., Yang, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 344
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
Metadata
- Authors
- Qi, S.-M., Dong, J., Xu, Z.-Y., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-05-07
- Volume
- 12
- Pages
- 692574-692574
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3160556876
- Cited by
- 292
- References
- 99
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.